Soleus Capital Management, L.P.

$2.5B reported 13(f) long value · latest quarter 2026-03-31 · CIK 1802630 · EDGAR ↗

sum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away: $2.5B
ALL retained default holdings for this (filer, period), including NULL-value ones: 93
positions with no comparable holding in the prior quarter (kind new), 2026-03-31: 25
positions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record: 27

A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ methodology §13F ↗

Position changes — into 2026-03-31

by shares · Δ value · filing link · how changes are classified §

Position changes into quarter 2026-03-31
position matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match `identity_reconciled_by_cusip`	the reported share count is unchanged across the pair; this build's data classified the change from its reported value; builds from 2026-09-10 on read it as NO CHANGE `classified_by_value` · EXIT = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · NO CHANGE = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an ADD or a TRIM (NEW / ADD / TRIM / EXIT / NO CHANGE) · NO PRIOR = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake	derived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero	reported unit changed across the pair (SH↔PRN); the share delta is withheld rather than fabricated `shares_unit_mismatch`	Prev value	Curr value	Prev shares	Curr shares
position key `pos:16881` · issuer key `iss:1079` COM	ADD	+$65.9M	+212,028	$232M	$298M	941,059	1,153,087
position key `pos:10390` · issuer key `iss:416` COM	TRIM	−$33.8M	−523,880	$180M	$147M	1,808,258	1,284,378
position key `pos:17263` · issuer key `iss:1795` COM	ADD	+$40.3M	+890,007	$93.6M	$134M	3,139,312	4,029,319
position key `pos:17234` · issuer key `iss:981` COM	ADD	+$75.4M	+412,500	$42.6M	$118M	150,000	562,500
position key `sid:sec:prov:ab3bd82b93cc9c55eaac96fb008434de` · issuer key `cusip6:G6674U` ORD SHS	ADD	+$4.1M	+1,961,726	$110M	$114M	8,530,665	10,492,391
position key `pos:15016` · issuer key `iss:1868` COM	ADD	+$81.8M	+127,187	$29.2M	$111M	60,000	187,187
position key `pos:11142` · issuer key `iss:1475` COM NEW	TRIM	−$491K	−32,449	$107M	$106M	362,966	330,517
position key `pos:14756` · issuer key `iss:1904` COM	ADD	+$54.5M	+1,785,079	$27.5M	$82.0M	764,000	2,549,079
position key `pos:15525` · issuer key `iss:2023` SHS	ADD	+$32.7M	+648,500	$37.0M	$69.7M	1,322,364	1,970,864
position key `pos:13106` · issuer key `iss:14` COM	ADD	+$24.7M	+334,000	$38.4M	$63.1M	486,243	820,243
position key `pos:17000` · issuer key `iss:829` CL A	TRIM	−$14.6M	−157,533	$77.4M	$62.9M	887,000	729,467
position key `sid:sec:prov:b6aaf2a1d9a7b3e3e2f1185e3325ec7d` · issuer key `cusip6:374163` COM	ADD	+$31.1M	+18,218,659	$30.7M	$61.8M	23,290,000	41,508,659
position key `pos:17149` · issuer key `iss:1835` COM	TRIM	−$767K	−635,173	$59.1M	$58.3M	1,861,802	1,226,629
position key `pos:11808` · issuer key `iss:635` COM	ADD	+$23.1M	+539,915	$22.6M	$45.7M	910,000	1,449,915
position key `sid:sec:prov:4e7eb09ab13c64fd6730ede8dbc988b8` · issuer key `cusip6:08659B` COM	ADD	−$33.6M	+1,819,936	$77.2M	$43.6M	2,534,565	4,354,501
position key `pos:15131` · issuer key `iss:87` COM	ADD	+$15.7M	+61,650	$27.8M	$43.6M	70,000	131,650
position key `sid:sec:prov:eb359106a5c4d721cdc955ced4da0795` · issuer key `cusip6:87164F` COM	TRIM	−$6.9M	−520,202	$47.2M	$40.3M	2,247,110	1,726,908
position key `pos:17511` · issuer key `iss:963` COM	NEW	+$38.8M	+1,274,000	$0	$38.8M	—	1,274,000
position key `sid:sec:prov:3402bbe7c4ba34aeef0c97588550f290` · issuer key `cusip6:641288` COM	ADD	−$3.2M	+228,999	$41.7M	$38.6M	2,703,208	2,932,207
position key `pos:10996` · issuer key `iss:2155` SHS	ADD	+$2.1M	+15,000	$34.9M	$37.0M	567,500	582,500
position key `pos:11504` · issuer key `iss:1236` COM	TRIM	−$8.3M	−173,308	$45.3M	$37.0M	573,614	400,306
position key `pos:11035` · issuer key `iss:266` COM	TRIM	−$41.7M	−669,428	$78.4M	$36.8M	1,320,000	650,572
position key `pos:17166` · issuer key `iss:1492` COM	NEW	+$35.1M	+2,067,000	$0	$35.1M	—	2,067,000
position key `pos:13569` · issuer key `iss:975` COM	ADD	+$2.1M	+276,900	$27.6M	$29.7M	299,399	576,299
position key `pos:13344` · issuer key `iss:2148` ORD SHS CL A	TRIM	+$889K	−65,647	$24.2M	$25.1M	587,000	521,353
position key `pos:17751` · issuer key `iss:1214` COM	NEW	+$24.4M	+203,000	$0	$24.4M	—	203,000
position key `sid:sec:prov:dbdd1ea895d57b4689152f8bb7b4c066` · issuer key `cusip6:68621F` COM	ADD	−$27.8M	+100,000	$51.7M	$23.9M	9,985,951	10,085,951
position key `pos:13186` · issuer key `iss:1273` COM	ADD	+$19.2M	+99,000	$4.6M	$23.8M	20,000	119,000
position key `sid:sec:prov:fd61a14f8c16900d70648b14bc187bfb` · issuer key `cusip6:05463X` COM	TRIM	−$17.0M	−527,685	$39.5M	$22.5M	1,206,855	679,170
position key `pos:11660` · issuer key `iss:1893` COM	TRIM	−$5.7M	−223,486	$28.1M	$22.4M	608,958	385,472
position key `pos:15581` · issuer key `iss:2131` SHS	NEW	+$21.2M	+192,000	$0	$21.2M	—	192,000
position key `sid:sec:prov:5acb3fdf8cac3eec6cd20dcb98ac92d0` · issuer key `cusip6:157085` COM	ADD	+$11.3M	+6,753,700	$8.2M	$19.6M	4,000,000	10,753,700
position key `pos:17822` · issuer key `iss:1820` COM	ADD	+$8.1M	+720,000	$11.3M	$19.3M	900,000	1,620,000
position key `sid:sec:prov:1e37f227d26a900c417273e355bd6875` · issuer key `cusip6:21077P` COM	NEW	+$18.2M	+6,963,141	$0	$18.2M	—	6,963,141
position key `pos:13488` · issuer key `iss:1918` COM	NEW	+$17.9M	+2,002,000	$0	$17.9M	—	2,002,000
position key `pos:12517` · issuer key `iss:1997` COM	NEW	+$17.0M	+292,000	$0	$17.0M	—	292,000
position key `pos:17702` · issuer key `iss:1818` COM	NEW	+$16.2M	+546,000	$0	$16.2M	—	546,000
position key `sid:sec:prov:19588aa5d3ea91e99dd9f4e2dc8228b5` · issuer key `cusip6:875372` COM NEW	NEW	+$15.0M	+783,000	$0	$15.0M	—	783,000
position key `sid:sec:prov:48ac0f50c981e01f7c5af17d58a117cf` · issuer key `cusip6:67080M` COM	TRIM	−$8.6M	−281,231	$23.1M	$14.5M	1,219,394	938,163
position key `sid:sec:prov:a469da6cabfc03832e3d85a7bff09e97` · issuer key `cusip6:M96088` COM	ADD	+$9.6M	+577,000	$3.5M	$13.1M	150,000	727,000
position key `pos:10212` · issuer key `iss:1665` COM	ADD	+$720K	+25,000	$11.0M	$11.8M	268,500	293,500
position key `pos:16094` · issuer key `iss:512` COM	NEW	+$11.5M	+285,531	$0	$11.5M	—	285,531
position key `pos:14904` · issuer key `iss:1899` COM	ADD	+$9.9M	+309,912	$421K	$10.3M	10,000	319,912
position key `sid:sec:prov:71e6d7a9978be392e4db6948ea1b496a` · issuer key `cusip6:68752L` COM	ADD	+$435K	+90,000	$9.3M	$9.8M	525,447	615,447
position key `sid:sec:prov:3c51cfeec4a5be695bdb08ebfaa41e00` · issuer key `cusip6:03969F` COM	TRIM	−$7.2M	−260,000	$17.0M	$9.8M	711,983	451,983
position key `pos:11535` · issuer key `iss:1757` COM	ADD	+$9.3M	+440,000	$88.6K	$9.4M	10,000	450,000
position key `sid:sec:prov:3c1bdde45f78766466db92da273259f5` · issuer key `cusip6:30052C` COM	ADD	+$2.1M	+1,175,360	$7.1M	$9.2M	1,070,000	2,245,360
position key `sid:sec:prov:59cedce491af5848a83a9f890d8ec6fe` · issuer key `cusip6:H82027` ORDINARY SHARES	NEW	+$9.2M	+1,850,000	$0	$9.2M	—	1,850,000
position key `sid:sec:prov:bf437640b37b30ed62d091e5e9de5808` · issuer key `cusip6:29337E` COM	TRIM	−$6.7M	−794,131	$15.8M	$9.1M	1,025,000	230,869
position key `pos:15950` · issuer key `iss:970` COM	ADD	+$6.8M	+106,000	$2.0M	$8.8M	25,000	131,000
position key `pos:15034` · issuer key `iss:573` COM	TRIM	−$77.3M	−1,157,094	$86.1M	$8.8M	1,297,094	140,000
position key `sid:sec:prov:c07b19289bd1953ef889bf232426771d` · issuer key `cusip6:81734D` COM	TRIM	−$4.1M	−108,368	$10.7M	$6.6M	383,368	275,000
position key `sid:sec:prov:2452fdde4d0b3fb9db6ac52c91059345` · issuer key `cusip6:09075X` COM	NEW	+$6.0M	+416,599	$0	$6.0M	—	416,599
position key `sid:sec:prov:0492e747c8d37a4dab1ade9330576c2c` · issuer key `cusip6:75955J` COM	NEW	+$5.9M	+842,106	$0	$5.9M	—	842,106
position key `pos:12625` · issuer key `iss:544` COM	NEW	+$5.8M	+410,200	$0	$5.8M	—	410,200
position key `sid:sec:prov:c0680e314bfe2d1131f5c3d642c67920` · issuer key `cusip6:45258J` COM	TRIM	−$22.5M	−880,000	$28.2M	$5.7M	1,110,000	230,000
position key `sid:sec:prov:1910147dd0682cb840152de5838d5484` · issuer key `cusip6:55287L` COM	TRIM	−$7.6M	−230,003	$12.9M	$5.3M	408,900	178,897
position key `sid:sec:prov:4629488a5d372449ffa54969c78cc5e4` · issuer key `cusip6:4525EP` COM	NEW	+$5.0M	+4,500,000	$0	$5.0M	—	4,500,000
position key `sid:sec:prov:853ca021ff04669801b685877f2dabbb` · issuer key `cusip6:517125` COM	NEW	+$4.8M	+1,066,960	$0	$4.8M	—	1,066,960
position key `sid:sec:prov:a6062b7020b087adc81a7c6d38642d39` · issuer key `cusip6:29772L` COM	NEW	+$4.1M	+166,381	$0	$4.1M	—	166,381
position key `sid:sec:prov:03d750f8ea50214fdbd147c22363d0f6` · issuer key `cusip6:78397T` COM NEW	NEW	+$4.0M	+1,050,000	$0	$4.0M	—	1,050,000
position key `sid:sec:prov:84385008a6354d52d8f431948b8d3d1e` · issuer key `cusip6:74276L` COM	NEW	+$4.0M	+160,000	$0	$4.0M	—	160,000
position key `sid:sec:prov:862b191ccb923fc424f39385b48ce4f8` · issuer key `cusip6:86366E` SPONSORED ADS	TRIM	−$2.4M	−10,000	$6.3M	$3.9M	90,000	80,000
position key `sid:sec:prov:ab98bdc5d9f0946c8554aa4745533ba5` · issuer key `cusip6:878972` COM	NEW	+$3.8M	+121,684	$0	$3.8M	—	121,684
position key `sid:sec:prov:d2d26810594465634746ea83805ad7e9` · issuer key `cusip6:745848` COM	ADD	−$908K	+750,000	$4.5M	$3.6M	2,038,323	2,788,323
position key `sid:sec:prov:aca3aee6eccb69fff82edb5a5d294e77` · issuer key `cusip6:462260` COM	NEW	+$3.5M	+1,000,000	$0	$3.5M	—	1,000,000
position key `pos:17260` · issuer key `iss:165` SPONSORED ADR	TRIM	−$24.1M	−28,226	$26.7M	$2.6M	31,726	3,500
position key `sid:sec:prov:c560957b5581c9f7aa7d0a8046845dcb` · issuer key `cusip6:80401L` COM	NEW	+$2.3M	+414,359	$0	$2.3M	—	414,359
position key `pos:15725` · issuer key `iss:172` COM	NEW	+$1.8M	+28,479	$0	$1.8M	—	28,479
position key `sid:sec:prov:4f3f0dbc6f010cb94ff5053ef428025c` · issuer key `cusip6:45779A` COM	TRIM	−$342K	−104,292	$2.0M	$1.7M	1,150,000	1,045,708
position key `pos:14207` · issuer key `iss:973` COM PAR $.01	TRIM	−$6.8M	−38,250	$8.4M	$1.7M	48,500	10,250
position key `sid:sec:prov:16b2967c1b0bb76b6346bfde109e0bb6` · issuer key `cusip6:23284F` COM	NEW	+$1.4M	+300,000	$0	$1.4M	—	300,000
position key `pos:11549` · issuer key `iss:429` COM	TRIM	−$5.7M	−150,000	$7.1M	$1.4M	170,000	20,000
position key `pos:17634` · issuer key `iss:1286` COM NEW	TRIM	−$3.7M	−252,504	$5.0M	$1.3M	427,504	175,000
position key `sid:sec:prov:80b2dc76650ba8570604605af72092bf` · issuer key `cusip6:74907L` SPONSORED ADS	ADD	+$119K	+47,730	$361K	$480K	25,000	72,730
position key `pos:17421` · issuer key `iss:475` COM	TRIM	−$3.9M	−110,000	$4.3M	$385K	120,000	10,000
position key `sid:sec:prov:47170149b82e95e4444c881acffa67fc` · issuer key `cusip6:90240B` COM	TRIM	−$2.9M	−115,000	$3.3M	$383K	125,000	10,000
position key `sid:sec:prov:ca11044044ffdef73864119b9879be03` · issuer key `cusip6:852312` COM PAR $0.01	TRIM	−$203K	−5,000	$577K	$374K	25,000	20,000
position key `pos:17269` · issuer key `iss:128` COM	TRIM	−$6.2M	−129,000	$6.5M	$333K	135,000	6,000
position key `sid:sec:prov:9fd554b76cc510ac236cd887d1f06195` · issuer key `cusip6:75383L` COM	NEW	+$313K	+10,000	$0	$313K	—	10,000
position key `sid:sec:prov:fd7b61c158906c86402255a51c19f819` · issuer key `cusip6:766559` COM	TRIM	−$12.6M	−290,034	$12.9M	$270K	300,034	10,000
position key `sid:sec:prov:cc436d9af4067ff4382c62284d4ff9e5` · issuer key `cusip6:98985Y` COM	TRIM	−$2.4M	−90,000	$2.6M	$250K	100,000	10,000
position key `pos:13812` · issuer key `iss:1378` COM	TRIM	−$5.5M	−185,000	$5.8M	$245K	190,000	5,000
position key `sid:sec:prov:9c89115e7db9beb584c246be98849529` · issuer key `cusip6:471871` COM NEW	ADD	−$124K	+76,312	$366K	$242K	200,000	276,312
pos:10141 PUT	EXIT‡e	−$354M	−2,900,000	$354M	$0	2,900,000	—
pos:10608	EXIT‡e	−$3.6M	−100,000	$3.6M	$0	100,000	—
pos:11462	EXIT‡e	−$25.0M	−175,982	$25.0M	$0	175,982	—
pos:11747	EXIT‡e	−$8.0M	−2,162,162	$8.0M	$0	2,162,162	—
pos:12364	EXIT‡e	−$6.1M	−45,000	$6.1M	$0	45,000	—
pos:12631	EXIT‡e	−$941K	−11,000	$941K	$0	11,000	—
pos:13703	EXIT‡e	−$196K	−10,000	$196K	$0	10,000	—
pos:13935	EXIT‡e	−$1.7M	−69,874	$1.7M	$0	69,874	—
pos:14357	EXIT‡e	−$291K	−500	$291K	$0	500	—
pos:16076	EXIT‡e	−$31.3M	−639,000	$31.3M	$0	639,000	—
pos:16187	EXIT‡e	−$23.2M	−190,000	$23.2M	$0	190,000	—
pos:16822	EXIT‡e	−$2.5M	−70,000	$2.5M	$0	70,000	—
pos:17130	EXIT‡e	−$18.4M	−92,500	$18.4M	$0	92,500	—
pos:17472	EXIT‡e	−$8.6M	−212,710	$8.6M	$0	212,710	—
sid:sec:prov:0983c227d7f489fadce1abda0a417532	EXIT‡e	−$25.9M	−764,000	$25.9M	$0	764,000	—
sid:sec:prov:38a603ca9db8667eb0886b5fba5cc3fe	EXIT‡e	−$4.5M	−683,904	$4.5M	$0	683,904	—

Flags: no row carries a flag.

1–20 of the 100 changes on this page

Mark-to-market only (no share change) · 9

Positions whose share count is identical in both quarters; the value changed with price, not with a decision.

Positions held with no share change into quarter 2026-03-31
position matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match `identity_reconciled_by_cusip`	the reported share count is unchanged across the pair; this build's data classified the change from its reported value; builds from 2026-09-10 on read it as NO CHANGE `classified_by_value` · EXIT = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · NO CHANGE = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an ADD or a TRIM (NEW / ADD / TRIM / EXIT / NO CHANGE) · NO PRIOR = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake	derived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero	Prev value	Curr value	Prev shares	Curr shares
position key `sid:sec:prov:229e14d74796ced76bf47c69ba76757e` · issuer key `cusip6:268311` SPONSORED ADR	NO CHANGE	+$3.1M	$24.0M	$27.2M	7,309,254	7,309,254
position key `pos:14578` · issuer key `iss:2296` COM	NO CHANGE	+$351K	$19.5M	$19.8M	702,052	702,052
position key `sid:sec:prov:8cb65945c1d745d32abfa3ce25a4d2e9` · issuer key `cusip6:45719W` COM NEW	NO CHANGE	−$4.0M	$22.3M	$18.3M	10,875,000	10,875,000
position key `sid:sec:prov:3b4a08cf659449a1ac1d2ee41e501b50` · issuer key `cusip6:008064` COM NEW	NO CHANGE	−$1.1M	$12.3M	$11.2M	796,744	796,744
position key `sid:sec:prov:de0907d604dc0fc94b1a3f8dd009ab9f` · issuer key `cusip6:00534A` COM	NO CHANGE	−$9.0M	$19.0M	$10.0M	7,708,727	7,708,727
position key `sid:sec:prov:d5b8ae591253ff1bf9b2d55cf805085a` · issuer key `cusip6:12529R` COM STK	NO CHANGE	+$2.7M	$7.3M	$10.0M	3,803,942	3,803,942
position key `sid:sec:prov:37b91915f07af95197894a79df85a91e` · issuer key `cusip6:05338F` COM NEW	NO CHANGE	−$1.4M	$8.0M	$6.6M	441,978	441,978
position key `sid:sec:prov:da6009df94d75bf6125e284a1e4e13f1` · issuer key `cusip6:48576U` COM NEW	NO CHANGE	−$788K	$3.2M	$2.5M	440,000	440,000
position key `sid:sec:prov:be515631054470e2500985b7cc1d1245` · issuer key `cusip6:50180M` COM SHS	NO CHANGE	+$24.0K	$223K	$247K	10,000	10,000

Flags: no row carries a flag.

Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.

Truncated by Public Filings. Changes compare every position with a security identifier, new and exited included; holdings without one are counted, not compared. methodology §13F ↗

Reported positions — 2026-03-31

1–93 of 93 positions · $2.5B disclosed value over 93 rows · 0 undisclosed-value rows

View

This build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.

Positions Soleus Capital Management, L.P. reported for the quarter ended 2026-03-31, as that filer reported them
This list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names.	a position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing	value undisclosed on the filing: retained and counted, excluded from sums, never shown as $0	Shares	Wt
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	KRYSTAL BIOTECH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$298M	1,153,087	12.1%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	CELCUITY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$147M	1,284,378	5.9%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	TG THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$134M	4,029,319	5.4%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	INSULET CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$118M	562,500	4.8%
—	NOVOCURE LTD · ORD SHS CUSIP G6674U108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$114M	10,492,391	4.6%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	UNITED THERAPEUTICS CORP DEL · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$111M	187,187	4.5%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	PRAXIS PRECISION MEDICINES I · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$106M	330,517	4.3%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	VERICEL CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$82.0M	2,549,079	3.3%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	ALKERMES PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$69.7M	1,970,864	2.8%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	ANI PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$63.1M	820,243	2.6%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	GLOBUS MED INC · CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$62.9M	729,467	2.5%
—	GERON CORP · COM CUSIP 374163103 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$61.8M	41,508,659	2.5%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	TWIST BIOSCIENCE CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$58.3M	1,226,629	2.4%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	EDGEWISE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$45.7M	1,449,915	1.8%
—	BETA BIONICS INC · COM CUSIP 08659B102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$43.6M	4,354,501	1.8%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	ALNYLAM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$43.6M	131,650	1.8%
—	SYNDAX PHARMACEUTICALS INC · COM CUSIP 87164F105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$40.3M	1,726,908	1.6%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	INDIVIOR PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$38.8M	1,274,000	1.6%
—	NEUROPACE INC · COM CUSIP 641288105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$38.6M	2,932,207	1.6%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	LIVANOVA PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$37.0M	582,500	1.5%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	MIRUM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$37.0M	400,306	1.5%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	BIOMARIN PHARMACEUTICAL INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$36.8M	650,572	1.5%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	PROGYNY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$35.1M	2,067,000	1.4%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	INSPIRE MED SYS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$29.7M	576,299	1.2%
—	EDAP TMS S A · SPONSORED ADR CUSIP 268311107 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$27.2M	7,309,254	1.1%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	KINIKSA PHARMACEUTICALS INTL · ORD SHS CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$25.1M	521,353	1.0%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	MERCK & CO INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$24.4M	203,000	1.0%
—	ORGANOGENESIS HLDGS INC · COM CUSIP 68621F102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$23.9M	10,085,951	1.0%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	NATERA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$23.8M	119,000	1.0%
—	AXOGEN INC · COM CUSIP 05463X106 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$22.5M	679,170	0.9%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	VAXCYTE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$22.4M	385,472	0.9%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	ICON PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$21.2M	192,000	0.9%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	PHARVARIS N V · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$19.8M	702,052	0.8%
—	CERUS CORP · COM CUSIP 157085101 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$19.6M	10,753,700	0.8%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	TREVI THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$19.3M	1,620,000	0.8%
—	INHIBIKASE THERAPEUTICS INC · COM NEW CUSIP 45719W205 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$18.3M	10,875,000	0.7%
—	CONTEXT THERAPEUTICS INC · COM CUSIP 21077P108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$18.2M	6,963,141	0.7%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	VIR BIOTECHNOLOGY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$17.9M	2,002,000	0.7%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	XENON PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$17.0M	292,000	0.7%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	TRAVERE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$16.2M	546,000	0.7%
—	TANDEM DIABETES CARE INC · COM NEW CUSIP 875372203 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$15.0M	783,000	0.6%
—	NURIX THERAPEUTICS INC · COM CUSIP 67080M103 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$14.5M	938,163	0.6%
—	UROGEN PHARMA LTD · COM CUSIP M96088105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$13.1M	727,000	0.5%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	SIONNA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$11.8M	293,500	0.5%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	CORCEPT THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$11.5M	285,531	0.5%
—	JADE BIOSCIENCES INC · COM NEW CUSIP 008064206 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$11.2M	796,744	0.5%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	VERACYTE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$10.3M	319,912	0.4%
—	INVIVYD INC · COM CUSIP 00534A102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$10.0M	7,708,727	0.4%
—	C4 THERAPEUTICS INC · COM STK CUSIP 12529R107 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$10.0M	3,803,942	0.4%
—	ORTHOPEDIATRICS CORP · COM CUSIP 68752L100 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$9.8M	615,447	0.4%
—	ARCUS BIOSCIENCES INC · COM CUSIP 03969F109 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$9.8M	451,983	0.4%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	TANGO THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$9.4M	450,000	0.4%
—	EVOLUS INC · COM CUSIP 30052C107 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$9.2M	2,245,360	0.4%
—	SOPHIA GENETICS SA · ORDINARY SHARES CUSIP H82027105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$9.2M	1,850,000	0.4%
—	ENLIVEN THERAPEUTICS INC · COM CUSIP 29337E102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$9.1M	230,869	0.4%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	INHIBRX BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$8.8M	131,000	0.4%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	DEXCOM INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$8.8M	140,000	0.4%
—	SEPTERNA INC · COM CUSIP 81734D104 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$6.6M	275,000	0.3%
—	AVALO THERAPEUTICS INC · COM NEW CUSIP 05338F306 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$6.6M	441,978	0.3%
—	BIODESIX INC · COM CUSIP 09075X207 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$6.0M	416,599	0.2%
—	RELMADA THERAPEUTICS INC · COM CUSIP 75955J402 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$5.9M	842,106	0.2%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	CULLINAN THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$5.8M	410,200	0.2%
—	IMMUNOVANT INC · COM CUSIP 45258J102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$5.7M	230,000	0.2%
—	MBX BIOSCIENCES INC · COM CUSIP 55287L101 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$5.3M	178,897	0.2%
—	IMMUNIC INC · COM CUSIP 4525EP101 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$5.0M	4,500,000	0.2%
—	LARIMAR THERAPEUTICS INC · COM CUSIP 517125100 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$4.8M	1,066,960	0.2%
—	ETON PHARMACEUTICALS INC · COM CUSIP 29772L108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$4.1M	166,381	0.2%
—	SAB BIOTHERAPEUTICS INC · COM NEW CUSIP 78397T202 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$4.0M	1,050,000	0.2%
—	PROCEPT BIOROBOTICS CORP · COM CUSIP 74276L105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$4.0M	160,000	0.2%
—	STRUCTURE THERAPEUTICS INC · SPONSORED ADS CUSIP 86366E106 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$3.9M	80,000	0.2%
—	TECTONIC THERAPEUTIC INC · COM CUSIP 878972108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$3.8M	121,684	0.2%
—	PULMONX CORP · COM CUSIP 745848101 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$3.6M	2,788,323	0.1%
—	IOVANCE BIOTHERAPEUTICS INC · COM CUSIP 462260100 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$3.5M	1,000,000	0.1%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	ARGENX SE · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$2.6M	3,500	0.1%
—	KARYOPHARM THERAPEUTICS INC · COM NEW CUSIP 48576U205 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$2.5M	440,000	0.1%
—	SATELLOS BIOSCIENCE INC · COM CUSIP 80401L803 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$2.3M	414,359	0.1%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	ARROWHEAD PHARMACEUTICALS IN · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$1.8M	28,479	0.1%
—	INSPIREMD INC · COM CUSIP 45779A846 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$1.7M	1,045,708	0.1%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	INSMED INC · COM PAR $.01 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$1.7M	10,250	0.1%
—	CYTOMX THERAPEUTICS INC. · COM CUSIP 23284F105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$1.4M	300,000	0.1%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	CG ONCOLOGY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$1.4M	20,000	0.1%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	NEOGENOMICS INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$1.3M	175,000	0.1%
—	QUOIN PHARMACEUTICALS LTD · SPONSORED ADS CUSIP 74907L409 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$480K	72,730	0.0%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	COGENT BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$385K	10,000	0.0%
—	TYRA BIOSCIENCES INC · COM CUSIP 90240B106 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$383K	10,000	0.0%
—	STAAR SURGICAL CO · COM PAR $0.01 CUSIP 852312305 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$374K	20,000	0.0%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	ANAPTYSBIO INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$333K	6,000	0.0%
—	RAPPORT THERAPEUTICS INC · COM CUSIP 75383L102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$313K	10,000	0.0%
—	RIGEL PHARMACEUTICALS INC · COM CUSIP 766559702 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$270K	10,000	0.0%
—	ZYMEWORKS INC · COM CUSIP 98985Y108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$250K	10,000	0.0%
—	LB PHARMACEUTICALS INC · COM SHS CUSIP 50180M108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$247K	10,000	0.0%
verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred)	ORUKA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗	$245K	5,000	0.0%
—	JASPER THERAPEUTICS INC · COM NEW CUSIP 471871202 quarter ended 2026-03-31 filed filed 2026-05-14 +44d src ↗ ticker not yet mapped	$242K	276,312	0.0%

1–20 of 93 positions

Change kind and share change are in Position changes above; Congress overlap is planned.

One line per issuer, largest first; a row with no issuer key stands on its own line. Open a line for its rows as this filer reported them. The list holds every row this filer reported for the quarter. Issuer totals on the holders pages count each manager's own report once; that never removes a row here. how positions are grouped ↗

Book shape

2026-03-31 · concentration · vs tracked median · tick = median

Top-25 concentration: 76.1%below median 80.0%
Concentration index: 380 bpsbelow median 446 bps
Positions with value: 93 / 93median book 97.5 positions

Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.

holdings whose <value> did not parse — retained and counted, never zero-filled: 0 · share of the period's disclosed value held in the top-N positions; denominator is reported 13F value, not total assets: 76.1% · integer Herfindahl–Hirschman index in basis points over disclosed position values: 380 · QoQ moves: 120

Filing history

AVAILABLE QUARTERS

Available filing periods
Period	Source
2026-03-31	EDGAR ↗

PLANNED sector rotation · Congress overlap · signals for this filer

Complete source filings on SEC EDGAR

The complete filing on EDGAR.

The position list above is served from the published Public Filings build, each position as this filer reported it; where the page cannot embed every reported row, the list says how many it leaves out. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Public Filings decided on 2026-08-01 to serve this list from its published build; filings newer than this build are on EDGAR.

Open Soleus Capital Management, L.P.'s 13F filings on SEC EDGAR ↗

Notes on this data

Reported positions

Quarter-end holdings as filed

Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.

Share changes

Compare consecutive quarters

Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.

Coverage

A snapshot, not current holdings

Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.

A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗

13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.

Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.

Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.

Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.

Positions under confidential treatment may be omitted until a later amendment discloses them.

These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).